Quick Answer
PTC THERAPEUTICS, INC. reported Research And Development Expense of $455.25 million for the year ending 2025.
- PTC THERAPEUTICS, INC. showed a decrease of -14.8% in Research And Development Expense from 2024 to 2025.
- This data is from PTC THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $11.92 million | Q3 2012: $10.47 million | Q1 2013: $11.26 million | Q2 2013: $14.71 million | Q3 2013: $13.89 million | Q1 2014: $15.89 million | Q2 2014: $18.31 million | Q3 2014: $18.77 million | Q1 2015: $27.94 million | Q2 2015: $28.19 million | Q3 2015: $30.64 million | Q1 2016: $31.40 million | Q2 2016: $28.83 million | Q3 2016: $31.40 million | Q1 2017: $27.36 million | Q2 2017: $30.84 million | Q3 2017: $30.02 million | Q1 2018: $31.36 million | Q2 2018: $32.61 million | Q3 2018: $54.37 million | Q1 2019: $52.57 million | Q2 2019: $59.98 million | Q3 2019: $63.08 million | Q1 2020: $90.11 million | Q2 2020: $176.53 million | Q3 2020: $93.00 million | Q1 2021: $134.51 million | Q2 2021: $125.48 million | Q3 2021: $130.85 million | Q1 2022: $140.08 million | Q2 2022: $157.26 million | Q3 2022: $165.46 million | Q1 2023: $195.12 million | Q2 2023: $185.87 million | Q3 2023: $164.21 million | Q1 2024: $116.13 million | Q2 2024: $132.17 million | Q3 2024: $161.41 million | Q1 2025: $108.97 million | Q2 2025: $112.99 million | Q3 2025: $100.16 million.
- Over the full 15 years of available data (2011 to 2025), PTC THERAPEUTICS, INC.'s Research And Development Expense has grown by 675.9%.
- Historical annual values: Fiscal year 2025: $455.25 million | Fiscal year 2024: $534.48 million | Fiscal year 2023: $666.56 million | Fiscal year 2022: $651.50 million | Fiscal year 2021: $540.68 million | Fiscal year 2020: $477.64 million | Fiscal year 2019: $257.45 million | Fiscal year 2018: $171.98 million | Fiscal year 2017: $117.46 million | Fiscal year 2016: $117.63 million | Fiscal year 2015: $121.82 million | Fiscal year 2014: $79.84 million | Fiscal year 2013: $54.88 million | Fiscal year 2012: $46.14 million | Fiscal year 2011: $58.68 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: